

**Amendments to the Claims**

13. (previously amended) A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a pharmaceutical composition comprising a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives at a dose effective to normalize blood glucose.
14. (original) A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, wherein the administration occurs within the first 72 hours following a myocardial infarction.
15. (original) A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a GLP-1 derivative at a dose effective to normalize blood glucose.
16. (original) The method of Claim 15, wherein the GLP-1 derivative is a GLP-1 analog having an acylated lysine  $\epsilon$ -amino group.
17. (original) The method of Claim 13, wherein the compound is complexed with a divalent metal cation.
18. (previously amended) The method of Claim 13, wherein the pharmaceutical composition further comprises a preservative selected from the group consisting of meta-cresol and phenol.
19. (original) The method of Claim 13, wherein the compound is selected from the group consisting of Val8 -GLP-1(7-37), Gly 8 -GLP-1(7-37), GLP-1(7-37), and GLP-1(7-36)NH<sub>2</sub>.
- 20-21 (canceled)
22. (previously added) The method of Claim 13, wherein the pharmaceutical composition further comprises a buffer.
23. (previously added) The method of claim 13, wherein the composition is administered at a dose effective to target blood glucose levels from about 4.1 mM to 7.5 mM.

Serial No. 09/834,229

24. (previously added) The method of claim 14, wherein the compound is administered at a dose effective to target blood glucose levels from about 4.1 mM to 7.5 mM.
25. (previously added) The method of claim 16, wherein the compound is administered at a dose effective to target blood glucose levels from about 4.1 mM to 7.5 mM.
26. (canceled)